Selecting the right trial partner: Considerations for psychedelic studies
ICON has deep multinational presence, operational infrastructure, and proven expertise in complex CNS studies. Most importantly, sponsors need CROs and sites that approach psychedelic trials as a genuinely novel operational challenge — not a conventional psychiatric trial with a longer session visit.
-
100
mood disorder studies -
13,900
patients -
3,000+
sites worldwide
With a global network spanning the US, Europe, and beyond, ICON can seamlessly manage cross-regional programmes, coordinating DEA licensing in the US alongside EU authorisations, activating sites efficiently in multiple jurisdictions, and standardising training and execution to reduce variability. Our extensive experience in mood disorders, including over 100 studies with more than 13,900 patients across 3,000-plus sites worldwide in the past five years, provides the operational rigour required for psychedelic trials. Our network of established relationships with hundreds of psychedelic-experienced sites across multiple countries supports rapid site selection and activation across studies of any scale.
Sponsors benefit from ICON’s ability to deploy standardised processes at scale, leverage a dedicated global psychiatry site network for faster startup, and apply refined training programmes for investigators, raters, and session monitors. This minimises costly delays, ensures consistent data quality across regions, and provides the regulatory and logistical support needed to advance programmes efficiently from Phase II through to approval.
Navigating psychedelic clinical trials:
Operational and regulatory considerations for sponsors
As the demand for innovative mental health therapies grows, successful development hinges on rigorous execution across borders. For sponsors developing psychedelic therapies, selecting partners with experience in complex CNS trials and multinational regulatory environments can be a key factor in navigating this evolving research.
For sponsors interested in how these considerations apply in practice:
Read our new case study to see how regulatory coordination and proactive site activation supported timely study start‑up in a multinational psychedelic clinical trial, or contact us to discuss how we can support your development objectives.